Some notable properties of the standard oncology Phase I design.

about

A phase 1 and pharmacodynamic study of decitabine in combination with carboplatin in patients with recurrent, platinum-resistant, epithelial ovarian cancer Modified toxicity probability interval design: a safer and more reliable method than the 3 + 3 design for practical phase I trials.

P2860

Q34091420-86B66C55-DB17-411B-AE4B-148EF4213512 Q38097422-64D38A3E-9042-4C33-AF5F-DEF30D30773A

P2860

Some notable properties of the standard oncology Phase I design.

Item

http://www.wikidata.org/entity/Q45978270

description

2009 nî lūn-bûn

@nan

2009年の論文

@ja

2009年学术文章

@wuu

2009年学术文章

@zh-cn

2009年学术文章

@zh-hans

2009年学术文章

@zh-my

2009年学术文章

@zh-sg

2009年學術文章

@yue

2009年學術文章

@zh

2009年學術文章

@zh-hant

name

Some notable properties of the standard oncology Phase I design.

@en

Some notable properties of the standard oncology Phase I design.

@nl

type

Item

label

Some notable properties of the standard oncology Phase I design.

@en

Some notable properties of the standard oncology Phase I design.

@nl

prefLabel

Some notable properties of the standard oncology Phase I design.

@en

Some notable properties of the standard oncology Phase I design.

@nl

P1476

Some notable properties of the standard oncology Phase I design.

@en

P2093

Gregory J Hather

http://www.w3.org/2001/XMLSchema#string

Howard Mackey

http://www.w3.org/2001/XMLSchema#string

P2860

Competing designs for phase I clinical trials: a review.

Phase I studies of chemotherapeutic agents in cancer patients: a review of the designs.

Risks and benefits associated with novel phase 1 oncology trial designs.

Design and analysis of phase I clinical trials.

An evaluation of phase I clinical trial designs in the continuous dose-response setting.

Continual reassessment method: a practical design for phase 1 clinical trials in cancer.

Dose-finding in phase I clinical trials based on toxicity probability intervals.

Statistical properties of the traditional algorithm-based designs for phase I cancer clinical trials.

Modified Fibonacci search.

Dose finding using the biased coin up-and-down design and isotonic regression.

P304

543-555

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/10543400902802466

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2009-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

24346832

http://www.w3.org/2001/XMLSchema#string

P698

19384695

http://www.w3.org/2001/XMLSchema#string

P818

0808.0359

http://www.w3.org/2001/XMLSchema#string

Some notable properties of the standard oncology Phase I design.

about

P2860

P2860

Some notable properties of the standard oncology Phase I design.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P5875

P698

P818

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P5875

P698

P818